CG
EIGR

Cutler Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Cutler Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$2K – 5888
2022
Q1 		$2K Buy
+50
New +$7.9K ﹤0.01% 4819
2021
Q2 		– Sell
-170
Closed -$1K – 6550
2021
Q1 		$1K Buy
170
+33
+24% +$10.4K ﹤0.01% 5445
2020
Q4 		$7K Buy
+137
New +$39.3K ﹤0.01% 3479

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Cutler Group's EIGR Position: Q1 2024 in Review

Cutler Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 33 shares.

Cutler Group first reported a position in EIGR in Q4 2015 and held it in 13 quarters. The position peaked at $26K in Q4 2015. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Cutler Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 33 Eiger BioPharmaceuticals, Inc. shares in Q1 2024.
  • Cutler Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2015 and held it in 13 quarters.
  • Cutler Group's Eiger BioPharmaceuticals, Inc. position peaked at $26K in Q4 2015.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.